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Abstract
OBJECTIVE: To evaluate the effect of Fuzhengpai-
du granule (FZPDG) on immune activation mole-
cules CD38 and human leukocyte antigen-D relat-
ed (HLA-DR) on CD4+ and CD8+ cells in HIV/AIDS
patients, and to explore the underlying mechanism
of this therapy.
METHODS: Plasma changes in CD3+, CD4+, CD8+,
CD3+CD4+CD38+ , CD3+CD4+HLA-DR+ , CD3+
CD8+CD38+, and CD3+CD8+HLA-DR+levels in HIV/
AIDS patients treated with FZPDG for six months
were examined by flow cytometry and compared
with levels in healthy controls.
RESULTS: The clinical trial included 34 outpatients
with HIV/AIDS. Before treatment, plasma levels of
CD38+ and HLA-DR+ on CD4/CD8 cells were higher
than those in 28 health controls (P<0.05). There
were no significant changes in serum levels of
CD3+ , CD4+ , and CD8+ T cells between pretreat-
ment baseline versus after treatment, which were
82.85% ± 5.41% , 14.57% ± 10.31% and 54.55% ±
11.43% before treatment and 79.15% ± 8.21% ,
19.96% ± 9.58% and 56.36% ± 11.67% after treat-
ment, respectively (P>0.05). Plasma levels of CD3+
CD4+CD38+ and CD3+CD4+HLA-DR+were 2.3%±
2.2% and 7.8%±5.5% before treatment and 1.2%±
0.8% and 2.6%±1.0% after treatment, respectively.
Plasma levels of CD3+CD8+CD38+ and CD3+CD8+
HLA-DR+ were 41.4%±13.4% and 17.8%±11.3% be-
fore treatment, which changed to 27.1%±10.2% and
3.8%±2.4%after treatment, respectively (P<0.05).
CONCLUSION: HIV/AIDS patients exhibited an im-
mune activation profile following FZPDG treat-
ment. A potential mechanism of action for FZPDG
appears to lie in its ability to up-regulate CD38 and
HLA-DR levels on CD4+ T cells, and down-regulate
them on CD8+ cells, thereby modulating immune
activation of CD4+and CD8+ T cells.
© 2013 JTCM. All rights reserved.
Key words: HIV; Acquired immunodeficiency syn-
drome; Fuzhengpaidu granule; Activated-leukocyte
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INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) caused
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by the human immunodeficiency virus (HIV) has be-
come a public health issue. A series of Fuzhengpaidu
formulas were developed based on the basic concept of
"preventative treatment of disease" in Traditional Chi-
nese Medicine (TCM). Preliminary clinical trials have
found that such formulas could relieve clinical symp-
toms, improve immunologic function, and even reduce
HIV virus load in HIV/AIDS patients.1-4 However, the
mechanisms by which these formulations work remain
unclear. In the present study, we sought to investigate a
possible mechanism of action for Fuzhengpaidu gran-
ule (FZPDG) in HIV/AIDS treatment by assessing im-
mune activation. Activation was assessed by measuring
CD38 and human leukocyte antigen-D related
(HLA-DR) levels on CD4+ and CD8+ cells in patients
treated with granule for six months.
METHODS
Criteria for diagnosis, inclusion, and exclusion
The Western Medicine diagnostic criteria for HIV/
AIDS were formulated in reference to "AIDS diagnosis
and treatment guidelines" promulgated by the AIDS
group of the Society of Infectious Diseases, of the Chi-
nese Medical Association.5
Patients eligible for inclusion were those aged 18-65
years, met Western Medicine diagnostic criteria, had
never received any anti-HIV western medical or Chi-
nese medical therapy, and who had signed the in-
formed consent.
The exclusion criteria are as follows: (a) patients who
had severe liver failure, serious primary diseases involv-
ing the heart, lung, kidney or hematopoietic system, or
mental illness; (b) patients with primary or secondary
immunodeficiency caused by hormone or chemothera-
py; (c) patients with hematologic diseases or women
who were pregnant or lactating; or (d) patients who
had serious opportunistic infections.
Study design
A self-controlled design was used and healthy controls
were used for comparison.
Treatment
FZPDG (herbal concentrate-granules, China Resourc-
es Sanjiu Medical & Pharmaceutical Co, Ltd. Shen-
zhen, China) consists of Huangqi (Radix Astragali Mon-
golici), Rensen (Radix Ginseng), Chaobaizhu (Roasted
Rhizoma Atractylodis Macrocephalae), Fuling (Poria),
Chenpi (Pericarpium Citri Reticulatae), Sharen (Fructus
Amomi), Yiyiren (Semen Coicis), Bajitian (Radix Morin-
dae Officinalis), Rouconrong (Herba Cistanche Deserti-
colae), Yinyanghuo (Herba Epimedii Brevicornus), Lian-
qiao (Fructus Forsythiae Suspensae), Danggui (Radix An-
gelicae Sinensis), and Gancao (Radix Glycyrrhizae).
All HIV/AIDS patients enrolled received half of one sa-
chet of FZPDG orally, two times daily, with boiled wa-
ter for six months.
Outcome measures
Immune activation molecules CD38 and HLA-DR on
CD4+ and CD8+ cells in HIV/AIDS patients taking
Fuzhengpaidu granule were examined by flow cytome-
try (EPICS-XL, Beckman Coulter, Brea, CA, USA) be-
fore and after treatment. Antibodies were labeled with
various flours, including CD4-FITC, CD3-PC5,
CD38-PE, CD8-ECD, HLA-DR-PE, mouse IgG1-
PE, or hemolysin (1.5% Formaldehyde), all of which
were purchased from Beckman Coulter Company. Ex-
periments were performed in a biological safety cabinet
(ThermoFisher, Waltham, MA, USA) using a single
channel micropipettor (Gilson, Villiers-le-Bel, France).
A total of 5 mL peripheral blood was collected from
HIV/AIDS patients receiving FZPDG by EDTA-K3
anticoagulation vacuum tubes for testing at room tem-
perature. Two sampling tubes received the following
monoclonal antibody combination in strict accordance
with the operation instructions: CD4-FITC/CD38-PE/
CD8-ECD/CD3-PC5; CD4-FITC/HLA DR-PE/
CD8-ECD/CD3-PC5. All experiments were complet-
ed within 24 h of specimen collection.
Statistical analysis
The data were analyzed by SPSS 19.0 software (IBM,
Chicago, IL, USA). All data were summarized using
mean ± standard deviation. Comparisons of pre- and
post-treatment data were compared by t-test. The sig-
nificance level was 0.05.
RESULTS
General data
This 6-month clinical trial enrolled 34 outpatients
with HIV/AIDS and 28 healthy controls from August
2010 to June 2011 at the first affiliated hospital of
Henan University of TCM. We did not observe signifi-
cant differences in age or gender bias between HIV/
AIDS patients and healthy controls. HIV/AIDS pa-
tients included 18 males and 16 females, with an age
range of 33-59 (44±8) years. Healthy controls included
16 males and 12 females aged (45±5) years. The base-
line CD4+ T lymphocyte count in the HIV/AIDS pa-
tients was 38-595 (247±133) cells/mL. Specifically, 15
patients had a CD4 + T lymphocyte count of fewer
than 200 cells/mL and 7 had a count of more than
350 cells/mL.
Comparison of CD38 and HLA-DR on CD4 or CD8
cells between HIV/AIDS patients and healthy
controls
The HIV/AIDS patients had significantly higher
levels of CD3+CD4+CD38+ , CD3+CD4+HLA-
DR+, CD3+CD8+CD38+, and CD3+CD8+HLA-
DR + compared with healthy controls (P<0.05)
(Table 1).
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Changes in immune activation molecules on CD3+,
CD4+, CD8+T cells and the CD4+/CD8+ ratio from
pretreatment baseline after FZPDG treatment
The percent of CD3+, CD4+, and CD8+T cells and
the CD4+/CD8+ ratios before and after treatment are
shown in Table 2. The results indicate that there were
no significant changes in the percentages of CD3 + ,
CD4+ or CD8+ cells, or the CD4+/CD8+ ratio be-
tween the pretreatment baseline and the levels follow-
ing treatment.
Changes in immune activation molecules CD38 and
HLA-DR on CD4+ and CD8+ cells before and after
treatment are shown in Table 3. These data indicate sig-
nificant changes in the immune activation molecules
CD38 and HLA-DR on CD4+ and CD8+ cells follow-
ing treatment. The immune activation molecules on
CD3+CD4+CD38+ and CD3+CD4+HLA-DR+ in-
creased after treatment, whereas they decreased on
CD3+CD8+HLADR+ and CD3+CD8+CD38+ cells
(all P<0.05).
DISCUSSION
CD4 + T cells are the primary target cells of HIV.
When the body is infected with HIV, CD4 + T cell
counts decrease, resulting in an inverted CD4+/CD8+
T cell ratio. This leads to a decline in immune func-
tion and various opportunistic infections and tumors.5
The baseline CD4+ T cell count and CD4+/CD8+T
ratio were low in our study, consistent with changes in
CD4+ and CD8+T cell counts during HIV/AIDS pro-
gression.
During the course of HIV infection, immune activa-
tion serves as a powerful indicator of disease progres-
sion. Aberrant immune activation leads to sustained
HIV duplication, a hallmark of HIV infection and a
critical component of HIV pathogenesis.6 Aberrant im-
mune activation provides the cell substrates necessary
for persistent virus replication throughout the course
of HIV, inducing viral expression in cells latently infect-
ed with HIV. This ultimately leads to an inability to
sustain an adequate immune response to antigen.7,8 Im-
mune activation molecule levels increase during HIV/
AIDS disease progression9 and decrease with highly ac-
tive anti-retroviral therapy (HAART),10 which may im-
prove patient response and optimize immune recov-
ery.11 This activated state is reflected by spontaneous
lymphocyte proliferation, monocyte activation, expres-
sion of activation markers on CD4+ and CD8+T cells,
and increased secretion of proinflammatory cyto-
kines.12 Immune system activation is manifested by the
abnormal increase in proportion of CD4+ and CD8+
T lymphocytes expressing immune activation markers,
such as CD38 and HLA-DR.13,14 Our results showed
that the levels of the immune activation molecules
Index
CD3+CD4+CD38+
CD3+CD4+HLA-DR+
CD3+CD8+CD38+
CD3+CD8+HLA-DR+
HIV/AIDS (n=34)
2.4±2.2
1.2±0.8
41.4±13.4
27.1±10.2
Healthy controls (n=28)
1.2±0.5
0.7±0.3
29.9±13.1
16.8±7.3
T
2.722
3.306
3.384
4.490
P
0.010
0.007
0.002
0.001
Notes: HLA-DR: human leukocyte antigen-D related; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency
syndrome.
Table 1 Comparison of CD38 and HLA-DR on CD4 or CD8 cells between HIV/AIDS patients and healthy controls (%, xˉ ± s )
Time point
Before treatment
After treatment
T
P
n
34
34
-
-
CD3+
82.85±5.41
79.15±8.21
1.417
0.167
CD4+
14.57±10.31
19.96±9.58
-1.498
0.145
CD8+
54.55±11.43
56.36±11.67
-0.430
0.671
CD4+/CD8+
0.31±0.26
0.40±0.29
-0.865
0.394
Table 2 Changes in the CD3+, CD4+, CD8+ T cell percentages and the CD4+/CD8+ratio from baseline after treatment (%, xˉ ± s )
Time point
Before treatment
After treatment
T
P
n
34
34
-
-
CD3+CD4+CD38+
2.4±2.2
7.8±5.5
-3.386
0.002
CD3+CD4+
HLA-DR+
1.2±0.8
2.6±1.0
-3.946
0.001
CD3+CD8+
CD38+
41.4±13.4
17.8±11.3
5.306
0.001
CD3+CD8+
HLA-DR+
27.1±10.2
3.8±2.4
9.423
0.001
Table 3 Changes in immune activation molecules on CD4+ and CD8+ T cells from baseline after treatment (%, xˉ ± s )
Note: HLA-DR: human leukocyte antigen-D related.
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CD38 and HLA-DR on CD4 + and CD8 + cells in
HIV/AIDS patients were higher than those in healthy
controls, suggesting immune activation.
The consequences of immune activation are different
for CD4 + T and CD8 + T cells. Aberrant activation
leads to decreased CD4+ T cell counts, and impaired
function.15,16 Up to 40% of patients receiving HAART
had suboptimal CD4 + T cell recovery despite sus-
tained HIV-RNA viral suppression,17,18 suggesting a
mechanism connected with immune activation.19 That
is, despite expression of the immune activation markers
CD38 and HLA-DR to facilitate immunological re-
sponse against foreign antigens, CD4 + activation is
suppressed. This corresponds to the overall trend of
CD4+ T cell loss and dysfunction during HIV/AIDS
disease progression.
However, CD8+ T cell activation increases in propor-
tion to HIV replication in HIV/AIDS pathogenesis.17,20
Higher CD8 + T cell activation levels are associated
with a more rapid CD4+ T cell decline and clinical pro-
gression among untreated patients.21 Persistently high
CD8+ activation during HAART mediated viral sup-
pression predicts earlier mortality, independent of
CD4+ counts.22
Our study demonstrated that expression of the activa-
tion markers CD3 and HLA-DR on CD4+ T cells in-
creased, but decreased on CD8+ T cells after FZPDG
treatment (P<0.05). This suggests that FZPDG increas-
es expression of immune activation markers on CD4+
T cells, strengthens CD4+ immune function, and de-
creases expression of activation markers on CD8 + T
cells, which suppresses immune activation of CD8+ T
cells. Therefore, regulation of CD4+ and CD8+T cells
appears to be one of the mechanisms by which FZP-
DG functions in treating HIV/AIDS patients.
Furthermore, our results did not detect significant ef-
fects of FZPDG on CD4+T cells or the CD4+/CD8+
ratio, which might be because our course of treatment
was too short and sample size too small. Additional
study with a larger sample size and a longer course of
treatment is needed for confirmation. In addition, our
results are limited by the absence of controlled groups,
in particular HAART or placebo groups. Overall, our
study has provided new insights into the mechanism of
Chinese medicine in treating HIV/AIDS.
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